Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

NCT07024706 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG: Acalabrutinib
DRUG: Venetoclax

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]